Top Markets
Coin of the day
NervGen Pharma Corp. NervGen Pharma Corp.

NervGen Pharma Corp.

NGEN
株式のランク #16728
NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical... NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical company dedicated to discovering, advancing, and commercializing innovative drug therapies for neurological conditions involving nerve damage. Its flagship investigational therapy, NVG-291, is currently undergoing Phase 1 clinical trials, targeting significant neurological disorders such as spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. NervGen has also secured an exclusive licensing agreement with Case Western Reserve University. This partnership enables the company to research, advance, and commercialize a proprietary technology holding considerable therapeutic promise for SCI and a range of other nerve-related ailments. Established in 2017, NervGen Pharma Corp. maintains its headquarters in Vancouver, Canada.
株価
$3.78
最終同期: 2026-03-17
時価総額
$276.54M
変化(1日)
0.00%
変化(1年)
45.53%
CA
取引 NervGen Pharma Corp. (NGEN)

カテゴリー

NervGen Pharma Corp.(NGEN)の収益
Sep 2026 時点の収益 TTM: 0
NervGen Pharma Corp. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
NervGen Pharma Corp. の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差
$12.62B -
US
$6.02B -
NL
$2.23B -
US
$15.74B -
AU
- -
CH